Your search history is turned on.
Date: March 15, 2019 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
NVLN-12.31.2018-10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from...
NVLN-12.31.2018-10K 88 acquisition, the corporation is not controlled in fact by the acquirer through the ownership of voting shares. The acquisition of less than one-third of the voting shares of a corporation or of an equivalent undivided ownership interest in the voting shares of the corporation is deemed not to be acquisition of control of that corporation. Certain transaction...
NVLN-12.31.2018-10K Exhibit 31.1 CERTIFICATIONS I, Benjamin Harshbarger, certify that: 1. I have reviewed this annual report on Form 10-K of Novelion Therapeutics Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which ...
NVLN-12.31.2018-10K Exhibit 31.2 CERTIFICATIONS I, Michael D. Price, certify that: 1. I have reviewed this annual report on Form 10-K of Novelion Therapeutics Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such...
NVLN-12.31.2018-10K 103 Item 8. Consolidated Financial Statements and Supplementary Data. Page Report of Independent Registered Public Accounting Firm - Deloitte & Touche LLP Consolidated Balance Sheets as of December 31, 2018 and 2017 Consolidated Statements of Operations for the years ended December 31, 2018 and 2017 Consolidated Statements of Comprehensive Loss for the year...
SKM_C55819031414331 ...
SKM_C55819031414330 ...
Date: March 14, 2019 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Earnings Release 12.31.2018 Exhibit 99.1 Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Company achieves FY 2018 total net revenues of $130.4 million FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and Cambridge, MA, March 14, 2019 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceuti...
Date: February 14, 2019 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - 125452944_4 1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Corporation: Novelion Therapeutics Inc. (the Company) c/o Norton Rose Fulbright Canada LLP 1800 510 West Georgia Street, Vancouver, BC V6B 0M3 Item 2 Date of Material Change: February 4, 2019 and February 6, 2019 Item 3 News Release: ...
Date: February 6, 2019 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2019 Novelion Therapeutics Inc. (Exact Name of Registrant as specified in its charter) c/o Norton Rose Fulbright 1800 - 51...